Literature DB >> 8344854

The management of desmoid tumors.

J C Acker1, E H Bossen, E C Halperin.   

Abstract

PURPOSE: To determine the efficacy of different treatment modalities for desmoid tumors.
MATERIALS AND METHODS: We reviewed the treatment of 40 patients with histologically confirmed desmoid tumors seen at Duke University Medical Center between 1974 and 1990.
RESULTS: Radiotherapy was administered to 16 patients (Group I)--14 with recurrent disease s/p surgery and in two as initial treatment. The average size of the irradiated lesions was 9.3 +/- 3.9 X 8.4 +/- 3.5 cm. With a median follow-up of 57.5 months and a median administered dose of 5400 cGy (mean 5286 cGy, range 4960-5620 cGy), local control has been obtained in 15/16 patients (94%). Complete regression (5/16), partial regression (5/16), or stable disease (5/16) was produced in 15 patients while one patient failed and was salvaged via gross total resection. Continued regression has been seen up to 60 months after treatment. Fourteen patients underwent primary gross total resection and two underwent subtotal resection (Group II). None received post-operative radiotherapy. Three of 14 patients (21%) recurred after gross total resection. All three were salvaged with subsequent gross total resection. After subtotal resection, 2/2 patients recurred. With a mean follow-up of 52 months, 14 patients are without evidence of disease, one is dead with disease (unrelated cause of death), and one was lost to follow-up after recurrence. Eight patients have been treated with combinations of chemotherapy, NSAIDS, anti-estrogens, and immunotherapy with mixed results (Group III). A subset of seven patients with retroperitoneal disease taken from all three groups had large tumor burden (mean size 17 X 15 cm), an infiltrative nature, as well as a difficult location. The disease was surgically resectable in three patients. One is without evidence of disease 9 years after gross total resection alone. Disease has been stabilized with radiotherapy in the other two patients after multiple unsuccessful surgical resections. Of four patients with unresectable disease, two are dead of disease, one died of unrelated causes with disease, and regression of disease was obtained in the other with Gamma-interferon after unsuccessful treatment with tamoxifen and vincristine, doxorubicin, and cyclophosphamide chemotherapy.
CONCLUSION: Gross total resection is the indicated initial therapy, if it can be performed without significant disfigurement. Radiotherapy is also excellent for obtaining local control, even in patients with a large burden of recurrent disease. Doses in the range of 50 to 55 Gy give a chance of local control equal to that obtained with higher doses previously reported.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8344854     DOI: 10.1016/0360-3016(93)90501-l

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

1.  Adjuvant radiotherapy for gastrointestinal stromal tumor of the rectum.

Authors:  J Pollock; D Morgan; J Denobile; J Williams
Journal:  Dig Dis Sci       Date:  2001-02       Impact factor: 3.199

2.  Extra-abdominal fibromatosis (desmoid tumor) arising in the infratemporal fossa: a case report.

Authors:  M Corsten; P Donald; J Boggan; A Gadre; R Gandour-Edwards; W Nemzek
Journal:  Skull Base Surg       Date:  1998

Review 3.  Radiation therapy for the treatment of benign vascular, skeletal and soft tissue diseases.

Authors:  A Montero Luis; R Hernanz de Lucas; A Hervás Morón; E Fernández Lizarbe; S Sancho García; C Vallejo Ocaña; A Polo Rubio; A Ramos Aguerri
Journal:  Clin Transl Oncol       Date:  2008-06       Impact factor: 3.405

4.  Multifocal extra-abdominal desmoid tumor--diagnostic and therapeutic problems.

Authors:  F Maurer; F Horst; C Pfannenberg; M Wehrmann
Journal:  Arch Orthop Trauma Surg       Date:  1996       Impact factor: 3.067

5.  Prognostic factors for desmoid tumor: a surgical series of 233 patients at a single institution.

Authors:  Wei-Gen Zeng; Zhi-Xiang Zhou; Jian-Wei Liang; Hui-Rong Hou; Zheng Wang; Hai-Tao Zhou; Xing-Mao Zhang; Jun-Jie Hu
Journal:  Tumour Biol       Date:  2014-05-02

6.  Undervaluation of Radiotherapy for Gross Desmoid Tumors: The Need for Absolute Volume Assessment.

Authors:  Yeon Joo Kim; Si Yeol Song; Wanlim Kim; Jongseok Lee; Jin-Hee Ahn; Jeong Eun Kim; Hye Won Chung; Seong-Yun Jeong; Eun Kyung Choi
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

Review 7.  A systematic review of active treatment options in patients with desmoid tumours.

Authors:  X Yao; T Corbett; A A Gupta; R A Kandel; S Verma; J Werier; M Ghert
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

8.  Treatment and follow-up strategies in desmoid tumours: a practice guideline.

Authors:  M Ghert; X Yao; T Corbett; A A Gupta; R A Kandel; S Verma; J Werier
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

Review 9.  Updates on abdominal desmoid tumors.

Authors:  Bernardino Rampone; Corrado Pedrazzani; Daniele Marrelli; Enrico Pinto; Franco Roviello
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

Review 10.  Imatinib in the treatment of solid tumours.

Authors:  Florence Duffaud; Axel Le Cesne
Journal:  Target Oncol       Date:  2009-01-27       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.